2019-01-01から1年間の記事一覧
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma.Blood. 2019 Aug 29;134(9):761-764. doi: 10.1182/blood.2019000258. Epub 2019 Jul 12.PMID: 31300404 進行期の…
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.PMID: 31433920 背景核外搬出化合物の選択的阻害薬であるselinexorは、exportin 1 (XPO1)をブロックし…
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.PMID: 31262783 PMCID: PMC6695562 大量…
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.Blood. 2019 May 17. pii: blood-2018-10-879643. doi: 10.1182/blood-2018-10-879643.PMID: 31101627 SAKK 35/10はSwiss Group for Clinical…
Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma.Blood. 2019 Jul 12. pii: blood.2019000258.PMID: 31300404 DOI: 10.1182/blood.2019000258 進行期の濾胞性リンパ腫 follicular lympho…
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.J Clin Oncol. 2019 Jul 10;37(20):1732-1741.PMID: 31112475 DOI: 10.1200/JCO.1…
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.J Clin Oncol. 2019 Jul 20;37(21):1790-1799.PMID: 30939090 DOI: 10.1…
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.Br J Haematol. 2019 …
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.Blood. 2019 Jun 20;133(25):2664-2668.PMID: 31010846 doi: 10.1182/blood.2019000671. 多発性骨髄腫(MM)の治療効果判定クライテリ…
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.J Clin Oncol. 2019 Jun 1;37(16):1391-1402PMID: 30995176 doi: 10…
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol. 2019 Apr 20;37(12):984-991. do…
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 Mar 7;133(10):1011-1019 PMID: 30530801, DOI: 10.1182/blood-2018-10-879429 イブルチニブは，経口のブルトン型チロシンキナーゼ…
Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial. Bone Marrow Transplant. 2019 Feb 4 PMID: 30718802 D…
最近は中枢神経リンパ腫の論文を目にする機会が多い気がします。 尚，この論文で用いられているCNS-IPIについては，過去記事も参考にしてください。 kusarenaikai.hatenablog.com Integration of cell of origin into the clinical CNS International Progno…
Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019 Mar 1;37(7):589-597 PMID: 30653422, DOI: 10.1200/JCO.18.00685 目的 メルファラン 200 mg/m2の投与と…
Long‐term overall‐ and progression‐free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non‐Hodgkin lymphoma https://doi.org/10.1111/bjh.15814 治療歴のない進行期のindolent非ホジキンリンパ腫(iNHL)患者を対象と…
Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients doi: 10.1182/blood-2018-09-874396 第3相試験であるCLARION試験は，移植非適応の未治療多発性骨髄腫患者を対象とし，カルフィ…
Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. Lancet Haematol. 2019 Jan 28 PMID: 30704923, DOI: 10.1016/S2352-3026(18)30231-X 背景 急性骨髄性白血病患者は，寛解導…
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. PMID: 30237266, PMCID: PMC6355495, DOI: 10.3324/haematol.2018.200881…
Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. PMID: 30696997 DOI: 10.1038/s41409-019-0457-9 同種造血幹細胞移…
Viral, immunologic, and clinical features of primary effusion lymphoma. PMID: 30782610, DOI: 10.1182/blood-2019-01-893339 原発性体腔液リンパ腫(primary effusion lymphoma, PEL)はHIVに関連したアグレッシブリンパ腫であり，効果的なHIV治療が可能…
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.Lancet. 2019 Jan 19;393(10168):229-240PMID: 30522922, doi: 10.1016/S0140-6736(18)32984-2 背景…
Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma Br J Haematol. 2019 Feb;184(3):348-363. PMID: 30467845, doi: 10.1111/bjh.15661. 中枢神経原発リンパ腫(primary CNS lymphoma, PCNSL)の…
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2019 Jan 24;380(4):335-346. PMID: 30625070, DOI: 10.1056/NEJMoa1806311 背景 後天性の血栓性血小板減少性紫斑病(TTP)は，von Willebrand因子を切断するプロテ…
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. (N Engl J Med. 2018 Dec 27;379(26):2517-2528.) PMID: 30501481, PMCID: PMC6325637 [Available on 2019-06-27] DOI: 10.1056/NEJMoa1812836 背景 イブルチニブは201…
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. (L…
